Rhumbline Advisers Editas Medicine, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q4 2024

A detailed history of Rhumbline Advisers transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 140,717 shares of EDIT stock, worth $184,339. This represents 0.0% of its overall portfolio holdings.

Number of Shares
140,717
Previous 141,875 0.82%
Holding current value
$184,339
Previous $483,000 63.15%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025
SELL
$1.2 - $3.76 $1,389 - $4,354
-1,158 Reduced 0.82%
140,717 $178,000
Q3 2024

Nov 12, 2024
BUY
$3.39 - $5.96 $13,183 - $23,178
3,889 Added 2.82%
141,875 $483,000
Q2 2024

Aug 01, 2024
BUY
$4.67 - $7.28 $18,035 - $28,115
3,862 Added 2.88%
137,986 $644,000
Q1 2024

May 09, 2024
BUY
$7.03 - $11.07 $19,248 - $30,309
2,738 Added 2.08%
134,124 $995,000
Q4 2023

Feb 08, 2024
SELL
$6.25 - $11.11 $206 - $366
-33 Reduced 0.03%
131,386 $1.33 Million
Q3 2023

Nov 09, 2023
BUY
$6.92 - $9.31 $99,371 - $133,691
14,360 Added 12.27%
131,419 $1.03 Million
Q2 2023

Aug 08, 2023
BUY
$6.36 - $11.47 $35,883 - $64,713
5,642 Added 5.06%
117,059 $963,000
Q1 2023

May 11, 2023
SELL
$7.03 - $11.53 $499 - $818
-71 Reduced 0.06%
111,417 $808,000
Q4 2022

Feb 14, 2023
BUY
$8.32 - $13.21 $23,969 - $38,058
2,881 Added 2.65%
111,488 $989,000
Q3 2022

Nov 10, 2022
BUY
$12.16 - $19.42 $89,424 - $142,814
7,354 Added 7.26%
108,607 $1.33 Million
Q2 2022

Aug 11, 2022
BUY
$9.99 - $21.35 $286,792 - $612,915
28,708 Added 39.57%
101,253 $1.2 Million
Q1 2022

May 12, 2022
BUY
$14.08 - $27.63 $8,110 - $15,914
576 Added 0.8%
72,545 $1.38 Million
Q4 2021

Feb 10, 2022
SELL
$26.55 - $40.57 $50,498 - $77,164
-1,902 Reduced 2.57%
71,969 $1.91 Million
Q3 2021

Nov 12, 2021
BUY
$39.27 - $72.94 $66,012 - $122,612
1,681 Added 2.33%
73,871 $3.04 Million
Q2 2021

Aug 05, 2021
SELL
$31.29 - $56.64 $100,659 - $182,210
-3,217 Reduced 4.27%
72,190 $4.09 Million
Q1 2021

May 06, 2021
SELL
$39.71 - $90.58 $172,103 - $392,573
-4,334 Reduced 5.44%
75,407 $3.17 Million
Q4 2020

Feb 10, 2021
BUY
$27.07 - $84.35 $144,066 - $448,910
5,322 Added 7.15%
79,741 $5.59 Million
Q3 2020

Nov 12, 2020
SELL
$28.06 - $37.16 $332,426 - $440,234
-11,847 Reduced 13.73%
74,419 $2.09 Million
Q2 2020

Aug 13, 2020
BUY
$18.5 - $34.34 $225,737 - $419,016
12,202 Added 16.47%
86,266 $2.55 Million
Q1 2020

May 06, 2020
BUY
$14.88 - $32.78 $32,602 - $71,820
2,191 Added 3.05%
74,064 $1.47 Million
Q4 2019

Feb 05, 2020
BUY
$19.49 - $32.63 $119,161 - $199,499
6,114 Added 9.3%
71,873 $2.13 Million
Q3 2019

Oct 23, 2019
SELL
$22.49 - $26.81 $2,091 - $2,493
-93 Reduced 0.14%
65,759 $1.5 Million
Q2 2019

Aug 14, 2019
BUY
$20.48 - $27.76 $108,871 - $147,572
5,316 Added 8.78%
65,852 $1.63 Million
Q1 2019

May 01, 2019
SELL
$19.43 - $26.41 $9,637 - $13,099
-496 Reduced 0.81%
60,536 $1.48 Million
Q4 2018

Jan 31, 2019
BUY
$18.19 - $31.79 $365,255 - $638,343
20,080 Added 49.03%
61,032 $1.39 Million
Q3 2018

Nov 07, 2018
SELL
$27.65 - $38.39 $81,567 - $113,250
-2,950 Reduced 6.72%
40,952 $1.3 Million
Q2 2018

Aug 06, 2018
BUY
$31.4 - $41.01 $293,370 - $383,156
9,343 Added 27.03%
43,902 $1.57 Million
Q1 2018

May 02, 2018
BUY
$29.84 - $44.08 $34,316 - $50,692
1,150 Added 3.44%
34,559 $1.15 Million
Q3 2017

Nov 06, 2017
BUY
$15.81 - $24.01 $528,196 - $802,150
33,409
33,409 $802,000

Others Institutions Holding EDIT

# of Institutions
228
Shares Held
54.2M
Call Options Held
412K
Put Options Held
355K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email